

Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis

Arndt Vogel^a Richard S. Finn^b Marie-Hélène Blanchet Zumofen^c
Carolina Heuser^c Javier Sanchez Alvarez^c Michael Leibfried^d
Catherine R. Mitchell^e Sarah Batson^e Gabrielle Redhead^e
Vincent E. Gaillard^a Masatoshi Kudo^f

^aHannover Medical School, Hannover, Germany; ^bDivision of Hematology Oncology, Department of Medicine, University of California, Los Angeles, CA, USA; ^cF. Hoffmann-La Roche Ltd., Basel, Switzerland; ^dGenentech Inc., South San Francisco, CA, USA; ^eMtech Access Limited, Bicester, UK; ^fDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan

Keywords

Atezolizumab · Cancer immunotherapy · Hepatocellular carcinoma · Network meta-analysis

Abstract

Background: In 2020, atezolizumab-bevacizumab became the new standard of care (SOC) for first-line unresectable hepatocellular carcinoma (HCC) patients, following a decade where sorafenib was the preferred first-line treatment. In the last few years, a number of novel systemic treatments with non-inferiority and superiority to sorafenib have been approved as first-line treatments. **Objectives:** The objective of this systematic literature review (SLR) and network meta-analysis (NMA) was to compare randomised controlled trial evidence for atezolizumab-bevacizumab with globally relevant pharmacological comparators for first-line treatment of patients with unresectable HCC. **Methods:** Randomised controlled trials investigating first-line treatment of HCC in adults with no prior systemic

treatment were eligible for inclusion into the SLR and were retrieved from Embase, MEDLINE, and Evidence-Based Medicine (EBM) Reviews. Interventions of interest for the NMA included atezolizumab-bevacizumab, sorafenib, lenvatinib, durvalumab (including in combination with tremelimumab), cabozantinib (including in combination with atezolizumab), camrelizumab (including in combination with rivoceranib), pembrolizumab (including in combination with lenvatinib), and tislelizumab. Random effects NMA was conducted for survival endpoints within a Bayesian framework with an informative prior distribution for between-study heterogeneity. The hazard ratios for relative treatment effect were estimated with 95% credible intervals (CrIs). **Results:** The SLR identified 49 studies, of which eight formed a connected evidence network permitting the indirect treatment comparison of atezolizumab-bevacizumab with comparators of interest. The indirect comparisons suggested an improved overall survival (OS) with atezolizumab-bevacizumab versus most comparators. All indirect treatment comparison results for

atezolizumab-bevacizumab included the null value within the 95% CrI ($n = 1$) for OS and progression-free survival (PFS). **Conclusions:** The results of the NMA indicate atezolizumab-bevacizumab is associated with superior or comparable OS and PFS together with a manageable safety profile compared with globally relevant comparators in the unresected HCC indication. The findings support that atezolizumab-bevacizumab remains SOC for the management of first-line unresectable HCC patients.

© 2023 The Author(s).
Published by S. Karger AG, Basel

Introduction

Hepatocellular carcinoma (HCC) accounts for 75–90% of all primary liver cancer cases and is the third leading cause of cancer-related mortality worldwide [1–3]. In approximately 70–90% of cases, HCC occurs in patients with chronic liver disease and cirrhosis; hence, the major risk factors for HCC are chronic infection with hepatitis B and C viruses (HBV, HCV), excessive alcohol intake, obesity, type 2 diabetes, and smoking [1].

Prior to the introduction of new systemic therapies, sorafenib provided the only first-line systemic pharmacological treatment and was the standard of care (SOC) for unresectable HCC [4]. The oral multi-kinase inhibitor sorafenib was first licensed by the Food and Drug Administration (FDA) in 2007 [5], offering a statistically significant improvement in overall survival (OS) compared with placebo, with a median survival of 10.7 months [6].

Since 2017, new systemic therapies for advanced HCC are available, resulting in a major paradigm shift in the treatment pathway [4]. Lenvatinib was approved by the FDA as a first-line treatment for unresectable HCC in 2018, as the phase 3 randomised controlled trial (RCT) (REFLECT: NCT01761266) showed median OS non-inferiority compared with sorafenib [7].

In a phase 3 RCT evaluating the efficacy and safety of the combination regimen in patients with unresectable HCC (IMbrave150: NCT03434379), atezolizumab-bevacizumab showed clinically meaningful improvements to OS and progression-free survival (PFS) compared with sorafenib, which has led to current approval globally [8]. Atezolizumab-bevacizumab received approval from the FDA in 2020 and is now considered the SOC for first-line systemic therapy of unresectable HCC [5, 9–11]. Atezolizumab is a monoclonal antibody that binds to programmed cell death 1 ligand 1 (PD-L1) and prevents the interaction between PD-L1 and its receptors

[12, 13]. Bevacizumab is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody that targets VEGF to inhibit angiogenesis and tumour growth [14, 15].

While atezolizumab-bevacizumab is the preferred first-line treatment in many countries [8, 11, 16], a number of novel systemic treatments with non-inferiority to sorafenib have been approved as first-line treatments [16]. In Europe, sorafenib or lenvatinib is recommended as an alternative first-line treatment [11]. Most recently, durvalumab in combination with tremelimumab was also approved by the FDA (October 2022) and recommended for approval by the European Medicines Agency (January 2023) for the treatment of unresectable HCC, following phase 3 trial results (HIMALAYA: NCT03298451) identifying superiority compared with sorafenib, with a favourable safety profile [17].

The objective of this systematic literature review (SLR) and network meta-analysis (NMA) was to compare RCT evidence for atezolizumab-bevacizumab with globally relevant pharmacological comparators for first-line treatment of patients with unresectable HCC.

Methods

Search Strategy and Selection Criteria

An SLR was conducted to identify RCTs studying first-line treatment with systemic therapies for unresectable HCC in adults with no prior systemic treatment history. The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the PRISMA-P and PRISMA-NMA extension guidelines. Interventions of interest for the SLR included combination atezolizumab-bevacizumab, durvalumab (including in combination with tremelimumab), cabozantinib (including in combination with atezolizumab), camrelizumab (including in combination with rivoceranib, previously known as apatinib), lenvatinib, pembrolizumab (including in combination with lenvatinib), and sorafenib. Locoregional modalities were excluded. Eligible studies reported at least one outcome of interest: OS, PFS, or adverse events (AEs). Included studies were phase 3 RCTs published in English that met the inclusion criteria described above.

Publication records were retrieved from Embase, MEDLINE, and Evidence-Based Medicine (EBM) Reviews. Database searches were originally performed in May 2019, with updates conducted in March 2020 and September 2022 (online suppl. Table S1 [Supporting Information]); for all online suppl. material, see <https://doi.org/10.1159/000533166>. The database searches were supplemented by a hand search of scientific conferences, health technology assessment reports, clinical trial registries, and reference lists from included publications and relevant SLRs (online suppl. Table S2 [Supporting Information]). Records were screened by

title and abstract, followed by full-text review by two independent reviewers, with discrepancies resolved through discussion or through intervention of a third reviewer.

Source Data Analysis

Data were extracted by an analyst and checked by a second analyst. Two independent reviewers assessed the risk of bias (with discrepancies adjudicated by a third advisor) based on guidance from the Centre for Reviews and Dissemination [18].

The feasibility of conducting indirect comparisons of phase 3 trials investigating comparators with study data from multiple countries and approved/anticipated approval globally further referred to as globally relevant for first-line HCC was examined. Interventions of interest for the NMA were aligned with those of interest for the SLR in addition to tislelizumab. Tislelizumab was not approved at the time of the most recent database search but RATIONALE-301 data were identified in the SLR on the basis of the sorafenib treatment arm [19]. Outcomes of interest for the indirect comparisons included OS and PFS as time-to-event endpoints. Assessment of heterogeneity in the evidence network included qualitative assessment of study designs, outcome measures, and patient populations. Studies reporting PFS according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 response criteria by blinded independent review facility (as aligned with IMbrave150) were considered for inclusion. Subgroup analyses were conducted to investigate patient characteristics possibly affecting the treatment outcomes when imbalances were observed in the distribution of factors. Subgroup analyses were conducted to examine population differences in region, aetiology, alpha-fetoprotein (AFP), Eastern Cooperative Oncology Group performance status (ECOG PS), and Barcelona Clinic Liver Cancer (BCLC) status, where feasible.

Descriptive summary statistics were used to compare patient characteristics and safety outcomes. Indirect comparisons of treatment effects for the time-to-event endpoints (OS and PFS) were analysed using a generalised linear model with random effects (REs) within a Bayesian framework, which required the assumption of proportional hazards to be upheld. However, the assessment of proportional hazards was not formally conducted across the studies as the outlined approach to analysis is consistent with other published analyses in this area [20–23]. The traditional RE approach imprecisely estimates between-study heterogeneity when few studies are available for meta-analysis [24]. Therefore, informative priors were used for the heterogeneity of treatment effects across trials, given the limited number of studies available to inform each pairwise comparison in the Bayesian RE approach [25]. Hazard ratios (HRs) with 95% credible intervals (CrIs) and Bayesian posterior probability estimates of atezolizumab-bevacizumab being superior to the other treatments were calculated for each indirect comparison [26]. An improved benefit of atezolizumab-bevacizumab over comparators was inferred in instances where an HR is less than 0.9 and an improved benefit of the comparators was inferred in instances where an HR is greater than 1.1. By using informative priors for the heterogeneity of treatment effects across trials, CrIs are also affected by prior belief on the between-trial heterogeneity, instead of relying solely on the trials in the network to calculate the heterogeneity. This can impact the width of the intervals when comparing Bayesian and frequentist frameworks. All analyses were conducted using R version 3.4.2 and WinBUGs; specifically, the R2WinBUGs package was used [27].

Results

The most recent database search, conducted on 15 September 2022, identified 2,113 records; 74 underwent full-text review, and 41 were included. A further eight records were identified by hand searching, and 64 records were included based on the previous searches, conducted in May 2019 and March 2020. The SLR included a total of 113 publications reporting on 49 unique studies (Fig. 1).

The evidence network comprised eight studies identified in the SLR that investigated globally relevant treatments that were able to connect within a network containing IMbrave150 (online suppl. Fig. S1 [Supporting Information]): CheckMate 459 [28], COSMIC-312 [29], HIMALAYA [17], IMbrave150 [30], LEAP-002 [31], NCT03764293 [32], RATIONALE-301 [19], and REFLECT [7]. The remaining 41 unique studies in the SLR were unable to connect within the evidence network due to the studies investigating non-relevant comparators.

Assessment of the studies in the evidence network demonstrated inter-study variability in the study designs and populations (online suppl. Table S3 and S4 [Supporting Information]). Where reported, median follow-up was shorter with CheckMate 459 (15.2 and 13.4 months in the nivolumab and sorafenib arms, respectively), COSMIC-312 (13.3 months), IMbrave150 (15.6 months), and NCT03764293 (14.5 months) compared with the other studies in the network such as LEAP-002 (32.1 months), HIMALAYA (32.2–33.1 months), and REFLECT (27.7 months). NCT03764293 included patients that were younger in age (median 58 and 56 years in the combination and sorafenib arms, respectively) compared with the other studies in the network (median age range 60–67 years). COSMIC-312 included a smaller proportion of patients with BCLC C (65–68%) compared with the other studies in the network (range 76–86%). NCT03764293 and RATIONALE-301 included a larger proportion of patients with ECOG PS 1 (range 46–57%) compared with the other studies in the network (range 27–39%). CheckMate 459, COSMIC-312, and HIMALAYA included a smaller proportion of patients with HBV (range 29–31%) compared with the other studies in the network (range 42–77%). The proportion of patients enrolled from the Asia-Pacific region varied across studies, with three studies including a majority of patients from this region; RATIONALE-301 (63%), REFLECT (67%), and NCT03764293 (83%). The remaining studies included 25–43% of patients from Asia-Pacific regions. IMbrave150 included 73/501 (15%) of patients with a tumour thrombus in the main trunk and/or contralateral portal vein (PVTT stage Vp4), who are nearly always excluded from pivotal HCC trials (HIMALAYA, LEAP-002, RATIONALE-301, REFLECT) due to their poor prognosis [33]. Thus, a non-Vp4 data set from




Fig. 1. PRISMA flow diagram. EBMR, evidence-based medicine reviews; NMA, network meta-analysis; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SLR, systematic literature review.

IMbrave150 was included in the base-case analyses (and the full IMbrave150 data set is considered in a sensitivity analysis).

All trials in the network reported HRs for OS and PFS but the assessment of proportional hazards was not formally conducted. Tumour response for PFS was assessed using RECIST v1.1 criteria by blinded independent central review in seven of the eight studies. HIMALAYA reported PFS by investigator assessment only (not blinded independent central review) but was included in the analyses to permit indirect treatment comparisons with durvalumab (\pm tremelimumab).

While REFLECT reported PFS using RECIST v1.1 criteria by blinded independent central review for the total population, it only reported subgroup analyses of

PFS using the modified RECIST criteria by investigator assessment, and thus REFLECT was excluded from analyses exploring subgroups.

The risk of bias was generally low across the five trials that were reported as full publications, and risk of bias could not be assessed for LEAP-002, NCT03764293, and RATIONALE-301, which were reported as conference presentations only at this time. Lack of study blinding was the greatest concern for all included studies except LEAP-002, which was double-blinded.

OS is the most objective endpoint when comparing results from different trials and was the primary or co-primary endpoint for all studies. In the OS network, indirect treatment comparisons suggested improved

Table 1. NMA results: PFS and OS (atezolizumab plus bevacizumab vs. comparators)

HR (95% CrI)–probability of A + B being superior	OS	PFS
A + B versus sorafenib	0.68 (0.42–1.10); 96%	0.66 (0.27–1.59); 91%
A + B versus cabozantinib	NA	0.93 (0.24, 3.44); 58%
A + B versus cabozantinib + atezolizumab	0.75 (0.38–1.48); 83%	1.05 (0.29–3.88); 45%
A + B versus camrelizumab + rivoceranib	1.09 (0.56–2.14); 37%	1.26 (0.34–4.60); 26%
A + B versus durvalumab	0.79 (0.41–1.49); 81%	0.65 (0.17–2.29); 87%
A + B versus durvalumab + tremelimumab	0.87 (0.45–1.66); 70%	0.73 (0.20–2.57); 81%
A + B versus lenvatinib	0.74 (0.39–1.40); 87%	1.01 (0.27–3.63); 48%
A + B versus lenvatinib + pembrolizumab	0.88 (0.40–1.49); 67%	1.22 (0.24–5.74); 32%
A + B versus nivolumab	0.80 (0.42–1.49); 81%	0.71 (0.19–2.55); 83%
A + B versus tislelizumab	0.80 (0.42–1.52); 80%	0.59 (0.16–2.10); 89%

A + B, atezolizumab plus bevacizumab; CrI, credible interval; HR, hazard ratio; NA, not available; NMA, network meta-analysis; OS, overall survival; PFS, progression-free survival.

OS benefit with atezolizumab-bevacizumab versus cabozantinib-atezolizumab (HR 0.75 [95% CrI 0.38, 1.48]; with 83% Bayesian posterior probability of being superior), durvalumab (0.79 [95% CrI 0.41, 1.49]; 81%), durvalumab-tremelimumab (0.87 [95% CrI 0.45, 1.66]; 70%), lenvatinib (0.74 [95% CrI 0.39, 1.40]; 87%), lenvatinib-pembrolizumab (0.88 [95% CrI 0.40, 1.49]; 67%), nivolumab (0.80 [95% CrI 0.42, 1.49]; 81%), and tislelizumab (0.80 [95% CrI 0.42, 1.52]; 80%), and no difference against camrelizumab-rivoceranib (1.09 [95% CrI 0.56, 2.14]; 37%; Table 1).

Findings from an OS sensitivity analysis including all patients in IMbrave150 (i.e., including Vp4 patients) were consistent with the base-case analysis, with only minor changes in the point estimates (in favour of atezolizumab-bevacizumab) (online suppl. Table S5 [Supporting Information]). Subgroup analyses were conducted to examine population differences in region, aetiology, AFP, ECOG PS, and BCLC status (online suppl. Table S5 [Supporting Information]). The OS benefit was more robust with atezolizumab-bevacizumab than the comparators in the HBV and HCV analyses and more robust with atezolizumab-bevacizumab than the available comparators in the AFP <400 ng/mL analyses. Across the remaining subgroups explored, the results were similar with the base-case, with the exception of those versus camrelizumab-rivoceranib; the OS benefit was more robust with atezolizumab-bevacizumab than camrelizumab-rivoceranib in the Asia-Pacific region, in patients with ECOG PS 1, and in patients with BCLC B.

Indirect comparisons of PFS suggested improved benefit with atezolizumab-bevacizumab versus durvalumab (0.65 [95% CrI 0.17, 2.29]; 87%), durvalumab-tremelimumab (0.73 [95% CrI 0.20, 2.57]; 81%), nivo-

lumab (0.71 [95% CrI 0.19, 2.55]; 83%), and tislelizumab (0.59 [95% CrI 0.16, 2.10]; 89%). There was also evidence of a potential improved benefit of the comparators camrelizumab-rivoceranib (1.26 [95% CrI 0.34, 4.60]; 26%) and lenvatinib-pembrolizumab (1.22 [95% CrI 0.24, 5.74]; 32%). However, there was no evidence of an improved benefit of PFS with atezolizumab-bevacizumab versus cabozantinib (0.93 [95% CrI 0.24, 3.44]; 58%), cabozantinib-atezolizumab (1.05 [95% CrI 0.29, 3.88]; 45%), and lenvatinib (1.01 [95% CrI 0.27, 3.63]; 48%).

Findings from a PFS sensitivity analysis including all patients in IMbrave150 (i.e., including Vp4 patients) were consistent with the base-case analysis with only minor changes in the point estimates (in favour of atezolizumab-bevacizumab) (online suppl. Table S6 [Supporting Information]). Limited comparator data were available for subgroup analyses of PFS (online suppl. Table S6 [Supporting Information]). The PFS benefit was more robust with atezolizumab-bevacizumab than cabozantinib-atezolizumab in the Asia-Pacific region and non-viral patients. The PFS benefit was more robust with atezolizumab-bevacizumab than camrelizumab-rivoceranib in the Asia-Pacific region, in patients with HBV, and AFP <400 ng/mL. Across the remaining subgroups explored, the results were similar to the base-case.

The comparative assessment of AEs was performed qualitatively. Occurrence of all-grade treatment-related AEs (TRAEs) was higher with sorafenib, cabozantinib ± atezolizumab, lenvatinib ± pembrolizumab, and camrelizumab-rivoceranib compared with atezolizumab-bevacizumab (Table 2). Fewer TRAEs were reported with durvalumab ± tremelimumab, nivolumab, and tislelizumab compared with atezolizumab-bevacizumab. Patients receiving

Table 2. Summary of safety data reported by eligible studies in the network

Study	Treatment arm	Population	N analysed	All-grade TRAEs, n (%)	Grade 3–4 TRAEs, n (%)	All-grade TRSAEs, n (%)	Death due to AEs, n (%)	Treatment discontinuation due to AEs, n (%)
Yau et al. [28] 2022 CheckMate 459	Nivolumab	ITT	367	257 (70)	81 (22.1)	43 (11.7)	4 (1.1)	27 (7.4)
	Sorafenib	ITT	363	338 (93.1)	179 (49.3)	39 (10.7)	1 (0.28)	42 (11.6)
Kelley et al. [29] 2022 COSMIC-312	Cabozantinib plus atezolizumab	ITT	429	399 (93)	273 (63.6)	78 (18)	51 (12)	Led to discontinuation, any treatment: 58 (14) Led to discontinuation, both treatments: 26 (6)
	Sorafenib	ITT	207	186 (90)	95 (45.9)	16 (8)	23 (11)	16 (8)
	Cabozantinib	ITT	188	178 (95)	113 (60.1)	24 (13)	30 (16)	16 (9)
Abou-Alfa et al. [17] 2022 HIMALAYA	STRIDE	ITT	388	294 (75.8)	100 (25.8)	68 (17.5)	9 (2.3)	32 (8.2)
	Durvalumab	ITT	388	202 (52.1)	50 (12.9)	32 (8.2)	0 (0)	16 (4.1)
	Sorafenib	ITT	374	317 (84.8)	138 (36.9)	35 (9.4)	3 (0.8)	41 (11)
	T75 + durvalumab	ITT	152	106 (69.7)	32 (21.2)	28 (18.4)	2 (1.3)	13 (8.6)
Finn et al. [8, 30] 2020 IMbrave150	Atezolizumab plus bevacizumab	Rest of ITT population (non-Vp4)	285	247 (87)	125 (44)	65 (23)	5 (2)	Led to discontinuation, any treatment: 61 (21)
	Sorafenib	Rest of ITT population (non-Vp4)	133	126 (95)	61 (46)	20 (15)	1 (1)	Led to discontinuation, any treatment: 16 (12)
Finn et al. [31] 2022 LEAP-002	Lenvatinib plus pembrolizumab	ITT	395	381 (96.5)	243 (61.5)	NR	4 (1.0)	Led to discontinuation, any treatment: 71 (18) Led to discontinuation, both treatments: 22 (5.6)
	Lenvatinib plus placebo	ITT	395	378 (95.7)	224 (56.7)	NR	3 (0.8)	Led to discontinuation, any treatment: 42 (10.6) Led to discontinuation, both treatments: 18 (4.6)
Qin et al. [32] 2022, NCT03764293	Camrelizumab plus rivoceranib	ITT	272	265 (97.4)	219 (80.5)	66 (24.3)	1 (0.4)	Discontinuation of any treatment components: 66 (24.3) Discontinuation of all treatment components: 10 (3.7)
	Sorafenib	ITT	269	249 (92.6)	140 (52)	16 (5.9)	1 (0.4)	Discontinuation of any treatment components: 12 (4.5) Discontinuation of all treatment components: 12 (4.5)

Table 2 (continued)

Study	Treatment arm	Population	N analysed	All-grade TRAEs, n (%)	Grade 3–4 TRAEs, n (%)	All-grade TRSAEs, n (%)	Death due to AEs, n (%)	Treatment discontinuation due to AEs, n (%)
Qin et al. [19] 2022 RATIONALE-301	Tislelizumab	ITT	338	259 (76.6)	NR	40 (11.8)	3 (0.9)	37 (10.9)
	Sorafenib	ITT	324	311 (96)	NR	33 (10.2)	2 (0.6)	60 (18.5)
Kudo et al. [7] 2018 REFLECT	Lenvatinib	ITT	476	447 (94)	NR	84 (18)	11 (2)	63 (13.2)
	Sorafenib	ITT	475	452 (95)	NR	48 (10)	4 (1)	43 (9.1)

AE, adverse event; ITT, intent to treat; NR, not reported; STRIDE, 300 mg of tremelimumab for one dose plus 1,500 mg of durvalumab every 4 weeks; T75, 75 mg of tremelimumab every 4 weeks for four doses; TRAE, treatment-related adverse event; TRSAE, treatment-related serious adverse event.

atezolizumab-bevacizumab experienced more all-grade treatment-related serious AEs (TRSAEs) and more treatment discontinuation due to AEs than patients receiving any of the other comparators, except camrelizumab-rivoceranib, although it is noted the sorafenib-treated patients in IMbrave150 generally had a higher rate of all-grade TRSAEs and treatment discontinuations due to AEs than the sorafenib-treated patients in the comparator trials.

Discussion

This NMA compared globally relevant therapies in first-line treatment of patients with locally advanced or metastatic unresectable HCC and no prior systemic treatment history. The analysis was based on RCT evidence identified by an SLR, which permitted a series of robust indirect treatment comparisons. Results of the NMA demonstrated superior or comparable OS and PFS with atezolizumab-bevacizumab versus available comparators of interest.

All trials included in the network featured an open-label design, except LEAP-002, which may have influenced duration of treatment of the control arms (sorafenib) in other studies and safety endpoints. Inclusion of the HIMALAYA trial in the NMA of PFS (which reported investigator-assessed PFS only) was permitted to enable comparison of durvalumab and durvalumab-tremelimumab. IMbrave150 included a higher-risk population (including patients with PVTT

stage Vp4) compared with the comparator trials while still meeting its primary endpoints [8].

In indirect comparisons, OS offers the most objective assessment of clinical efficacy. In this analysis, clinical efficacy results remained largely consistent with primary findings when analysed by sensitivity analyses (including Vp4 patients in the IMbrave150 data set) and when analysed in subgroups of patients based on geographic region, aetiology, AFP, ECOG PS, and BCLC status. The OS benefit was more robust with atezolizumab-bevacizumab than the comparators in the HBV and HCV analyses and the available comparators in the AFP <400 ng/mL analyses. Furthermore, the OS benefit was more robust with atezolizumab-bevacizumab than camrelizumab-rivoceranib in the Asia-Pacific region, in patients with ECOG PS 1, and in patients with BCLC B. Across the remaining subgroups explored, the results were similar to the base-case with no additional benefit observed of atezolizumab-bevacizumab against camrelizumab-rivoceranib. Notably, the study investigating camrelizumab-rivoceranib (NCT03764293) was identified as a potential outlier in terms of age, BCLC status, ECOG PS, aetiology, and region; these patient characteristics suggest the study may not be fully appropriate for the indirect comparison and potentially residual differences in characteristics could have a prognostic impact on treatment effect that would bias the indirect comparison. It is important to highlight that the RE model accounts for additional uncertainty due to the between-study heterogeneity in the network. Hence, the NMA estimates for indirect comparisons have CrIs broader than the confidence intervals reported in head-to-head studies; for the

comparison of atezolizumab-bevacizumab with sorafenib, the OS estimate from the direct comparison in the base-case population was 0.68 (95% confidence interval: 0.51, 0.89).

Due to differences in the definitions of endpoints, inclusion and exclusion criteria, follow-up time, and duration of treatment across trials and treatment arms (e.g., deaths due to AEs and treatment discontinuations), meta-analysis of safety outcomes can be challenging. While comparison of reported AE occurrences was included, detailed comparisons of toxicity profiles were not feasible in this NMA. As such, the absolute safety numbers should be interpreted in the context of the differential impact of AEs on patients' lives and the differences in the follow-up time and treatment durations across trials and treatment arms. Issues with toxicity of sorafenib and lenvatinib have been well documented [34–36]. Atezolizumab-bevacizumab provides a different AE profile, reflected in the delayed time to deterioration of quality of life compared with sorafenib [8]. Further, immune-related AEs are a characterised risk with regimens using a cancer immunotherapy component [37].

A robust evidence network of trials was incorporated into this NMA. The indirect comparisons showed more favourable OS and PFS results for the anti-PD-L1 and anti-VEGF combination atezolizumab-bevacizumab compared with most single- or double-agent targeted systemic treatments.

Whilst the indirect comparisons provide evidence of a potential improved PFS benefit of the comparators camrelizumab-rivoceranib and lenvatinib-pembrolizumab, the study investigating camrelizumab-rivoceranib (NCT03764293) was identified as a potential outlier in terms of population, and the indirect comparison with lenvatinib-pembrolizumab is based on three studies in the chain of evidence with two common comparators (IMbrave150/REFLECT/LEAP-002), which increase the risk of bias and uncertainty in the estimate.

More frequent reporting of all-grade TRSAEs and AEs leading to treatment discontinuation was observed in IMbrave150 for atezolizumab-bevacizumab compared with the other studies, with the exception of camrelizumab-rivoceranib [32]. However, the overall effect of each treatment from a patient's perspective is not captured in a qualitative comparison of the occurrence of AEs.

The results of the current NMA are broadly consistent in terms of direction of treatment effect with those from previously conducted NMAs in first-line HCC [20–23, 38]. However, some differences can be observed in the methodology. The two most recently published NMAs from Fong et al. [38] and Fulgenzi et al. [23] were conducted using a frequentist approach with an RE or fixed-effect model, respectively, and a comparison of the results of these analyses with the current analysis is presented in

online supplementary Table S7 (Supporting Information). The current analysis was conducted using a Bayesian approach that accounted for study heterogeneity by employing an RE model with an informative prior distribution for between-study heterogeneity. Moreover, Fong et al. [38] generated pseudo-individual patient data from study-reported KM curves and pooled these data for atezolizumab-bevacizumab and sintilimab-bevacizumab, to generate a common arm for analysis that “combined anti-programmed-death and anti-VEGF pathway inhibitor monoclonal antibodies”; individual patient data were reconstructed and an HR generated for input in the NMA [38]. No other treatments were pooled into treatment nodes within the network presented by Fong et al. [38], thus indirect comparisons of atezolizumab-bevacizumab with the remaining comparators were not presented. The results presented by Fong et al. [38] for the comparison of combined anti-programmed-death and anti-VEGF pathway inhibitor monoclonal antibodies treatment (i.e., for atezolizumab-bevacizumab and sintilimab-bevacizumab biosimilar) with other comparators included in the current analyses are similar in terms of point estimates and direction of treatment effect for OS, but there are differences noted for the comparison with cabozantinib + atezolizumab and lenvatinib for PFS (online suppl. Table S7 [Supporting Information]). This is a consequence of the inclusion of data from ORIENT-32 [39] in the pooled atezolizumab-bevacizumab and sintilimab-bevacizumab data set, and thus the results are not directly comparable with the current analysis [38]. The results presented by Fulgenzi et al. [23] are aligned with the current analysis in terms of point estimates and direction of treatment effect for both OS and PFS, although the analysis by Fulgenzi et al. [23] does not include camrelizumab-rivoceranib, lenvatinib-pembrolizumab, and tislelizumab as comparators (online suppl. Table S7 [Supporting Information]). Notably, across both published analyses, the estimates of uncertainty (i.e., 95% CIs) are smaller in comparison with the current analysis (95% CrI). In Fulgenzi et al. [23], this is a consequence of conducting a fixed-effect model (i.e., the estimates therefore do not account for between-study heterogeneity and report narrower 95% CIs vs. estimates from an RE model). In Fong et al. [39], this is dependent on the fact of combining data across two studies for the intervention treatment (i.e., combined atezolizumab-bevacizumab and sintilimab-bevacizumab biosimilar), and so the data set for the intervention is larger, and therefore the indirect treatment comparisons are associated with less uncertainty.

The authors of the Fulgenzi et al. [23] NMA stated heterogeneity in the data sets in terms of patients with PVTT stage Vp4, which was not highlighted by Fong et al.

[38], but neither analysis addressed this heterogeneity in their analyses. In comparison, the current NMA excludes patients with PVT stage Vp4 from the IMbrave150 data set to align with the lower risk comparator study populations more closely, and a comprehensive exploration of multiple subgroup analyses was conducted for both outcomes. In addition, Fong et al. [38] and Fulgenzi et al. [23] included different comparators. The current analysis focused on systemic therapies, therefore locoregional therapies (such as selective internal radiotherapy, transarterial chemoembolization) were not considered. Due to the earlier search dates, Fong et al. [38] could not identify data for three comparators of interest for the current analysis (LEAP-002, NCT03764293, RATIONALE-301). While Fulgenzi et al. [23] used a broader set of comparators, the current analysis focused on newly globally relevant comparators for first-line treatment of unresectable HCC [23, 38].

This analysis should be interpreted with consideration of certain limitations. The indirect comparisons would be more robust if access to full study reports and patient-level data were available, particularly for the subgroup analyses that were not reported consistently across trials. As with all NMAs, this analysis assumes a similar distribution of effect modifiers in the evidence network. An imbalance of factors may lead to a biased estimation of relative effects. Whilst heterogeneity across the studies has been explored, this was limited for some comparators due to limited reporting of subgroup data. The current NMA included globally relevant comparators. Notably, first-line therapies tested and approved in China only were excluded from the current analysis (including sintilimab-IBI305 and donafenib) [16].

Due to the recent emergence of a number of novel systemic therapies for the treatment of unresectable HCC, variation in treatment pathways and follow-up may impact OS results. The development and implementation of second-line therapies for unresectable HCC also present a limitation [40]. Consequently, evolution of second-line systemic therapies and cancer immunotherapies in later lines may have impacted the OS in some studies. As a result, further research should continue to assess the efficacy of treatment pathways in patients with unresectable HCC. In addition, emerging adjuvant therapies in HCC might impact the overall patient journey and treatment algorithms in the near-to-mid-term future.

Conclusion

The results of the current NMA indicate that combination treatment with atezolizumab-bevacizumab is associated with superior or comparable OS and PFS together

with a manageable safety profile compared with globally relevant options in the unresectable HCC indication. The findings support that atezolizumab-bevacizumab remains the SOC for the management of first-line unresectable HCC patients [5, 9–11].

Key Points

- An SLR and an NMA were conducted to compare RCT evidence for atezolizumab-bevacizumab with comparators for first-line unresectable HCC.
- The SLR identified 49 studies, of which eight formed a connected evidence network to permit the indirect treatment comparison of atezolizumab-bevacizumab with cabozantinib (\pm atezolizumab), camrelizumab + rivoceranib, durvalumab (\pm tremelimumab), lenvatinib, pembrolizumab + lenvatinib, and tislelizumab.
- The results of the NMA indicate atezolizumab-bevacizumab is associated with superior or comparable (camrelizumab-rivoceranib) OS together with a manageable safety profile compared with globally relevant treatments.
- The findings support that atezolizumab-bevacizumab should remain SOC for the management of first-line unresectable HCC patients.

Statement of Ethics

This study is based exclusively on published literature. An ethics statement is therefore not applicable.

Conflict of Interest Statement

Arndt Vogel had been directly paid honoraria and has been paid consulting or advisory roles for AstraZeneca, BeiGene, Boehringer Mannheim, BMS, BTG, Eisai, GSK, Incyte, Ipsen, MSD, Hoffmann-La Roche, Servier, Sirtex, and Taiho. Richard Finn has been paid consulting/advisory roles for AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Eli Lilly, Merck, Hoffmann-La Roche, Genentech, CStone, and Hengrui. His institution has conducted research for Bayer, Bristol Myers Squibb, Eisai, Eli Lilly, Merck, Pfizer, Hoffmann-La Roche, and Genentech. Dr. Finn has participated in speakers' bureau for Genentech.

Masatoshi Kudo had been directly paid honoraria by Eisai, Chugai, Eli Lilly, Takeda, and Bayer. His institution has conducted research for Otsuka, Chugai, GE Healthcare, Taiho, AbbVie, EA Pharma, and Eisai. Marie-Helene Blanchet Zumofen, Carolina Heuser, Javier Sanchez Alvarez, and Vincent E. Gaillard are currently or have been during the past 2 years employed by Hoffmann-La Roche Ltd. Michael Leibfried is employed by Genentech Inc. Marie-Helene Blanchet Zumofen, Carolina

Heuser, Javier Sanchez Alvarez, Vincent E. Gaillard, and Michael Leibfried own stocks (currently or in the past 2 years) in Hoffmann-La Roche Ltd. Catherine R. Mitchell, Sarah Batson, and Gabrielle Redhead have no conflict of interest.

Funding Sources

This research was funded by F. Hoffmann-La Roche Ltd.

Author Contributions

Arndt Vogel, Richard Finn, Marie-Helene Blanchet Zumofen, Carolina Heuser, Javier Sanchez Alvarez, Michael Leibfried, Catherine R. Mitchell, Sarah Batson, Gabrielle Redhead, Vincent E. Gaillard, and Masatoshi Kudo contributed to the design and interpretation of findings. Catherine R. Mitchell, Sarah Batson, and

Gabrielle Redhead conducted the systematic review and statistical analyses. Sarah Batson wrote the first draft of the report with input from Arndt Vogel, Richard Finn, Marie-Helene Blanchet Zumofen, Carolina Heuser, Javier Sanchez Alvarez, Michael Leibfried, Catherine R. Mitchell, Gabrielle Redhead, Vincent E. Gaillard, and Masatoshi Kudo. All authors participated in the writing and editing of the manuscript and confirm they had full access to all the data in the study and accept responsibility to submit for publication.

Data Availability Statement

This manuscript makes use of publicly available data from published studies. All data generated during this study are included in this article and its online supplementary material files. Further enquiries can be directed to the corresponding author.

References

- 1 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*. 2007; 132(7):2557–76.
- 2 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 May;71(3):209–49.
- 3 Kaya E, Mazzolini GD, Yilmaz Y, Canbay A. Prevention of hepatocellular carcinoma and monitoring of high-risk patients. *Hepatol Forum*. 2022 Jan 9;3(1):33–8.
- 4 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. *Liver Int*. 2022;42(9):2067–79.
- 5 Food and Drug Administration. Nexavar. 2007.
- 6 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008 Jul 24;359(4):378–90.
- 7 Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. *Lancet*. 2018;391(10126):1163–73.
- 8 Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*. 2020;382(20):1894–905.
- 9 Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. *J Clin Oncol*. 2020 Dec 20;38(36):4317–45.
- 10 Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. *J Hepatol*. 2021 Oct;75(4):960–74.
- 11 Vogel A, Martinelli E, ESMO Guidelines Committee; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. *Ann Oncol*. 2021;32(6):801–5.
- 12 Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature*. 2014;515(7528):563–7.
- 13 Shah NJ, Kelly WJ, Liu SV, Choquette K, Spira A. Product review on the anti-PD-L1 antibody atezolizumab. *Hum Vaccin Immunother*. 2018; 14(2):269–76.
- 14 Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. *Biochem Biophys Res Commun*. 2005;333(2): 328–35.
- 15 Finn RS, Bentley G, Britten CD, Amado R, Busuttill RW. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. *Liver Int*. 2009 Feb;29(2):284–90.
- 16 Yang Y, Sun J, Wu M, Lau WY, Zheng S, Wang XH, et al. Chinese expert consensus on immunotherapy for hepatocellular carcinoma (2021 edition). *Liver Cancer*. 2022;11(6):511–26.
- 17 Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. *NEJM Evid*. 2022;1(8).
- 18 Centre for Reviews and Dissemination. Systematic Reviews. 2008. https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf.
- 19 Qin S, Kudo M, Meyer T, Finn R, Vogel A, Bai Y, et al. LBA36 Final analysis of RA-TIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. *Ann Oncol*. 2022;33:S1402–3.
- 20 Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. *JAMA Oncol*. 2020 Dec 1;6(12):e204930.
- 21 Liu W, Quan B, Lu S, Tang B, Li M, Chen R, et al. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis of randomized clinical trials. *Front Oncol*. 2021;11:771045.
- 22 Vogel A, Rimassa L, Sun H-C, Abou-Alfa GK, El-Khoueiry A, Pinato DJ, et al. Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis. *Liver Cancer*. 2021;10(3):240–8.
- 23 Fulgenzi M, Scheiner B, Korolewicz J, Stikas C, Gennari A, Vincenzi B, et al. Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials. *JHEP Rep*. 2023;5(5):100702.
- 24 Jackson D, Bowden J, Baker R. How does the DerSimonian and Laird procedure for random effects meta-analysis compare with its more efficient but harder to compute counterparts? *J Stat Plann Inference*. 2010;140(4): 961–70.
- 25 Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JP. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. *Stat Med*. 2015;34(6):984–98.
- 26 Bland JM, Altman DG. Statistics notes: bayesians and frequentists. *BMJ*. 1998; 317(7166):1151–60.

- 27 Sturtz S, Ligges U, Gelman A. R2WinBUGS: a package for running WinBUGS from R. *J Stat Softw.* 2005;12(3):1–6.
- 28 Yau T, Park J-W, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol.* 2022;23(1):77–90.
- 29 Kelley RK, Rimassa L, Cheng A-L, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2022;23(8):995–1008.
- 30 Breder VV, Vogel A, Merle P, Finn RS, Galle PR, Zhu AX, et al. IMbrave150: exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo)+ bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. *J Clin Oncol.* 2021;39(15 Suppl).
- 31 Finn R, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. LBA34 primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). *Ann Oncol.* 2022;33:S1401.
- 32 Qin S, Chan L, Gu S, Bai Y, Ren Z, Lin X, et al. LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. *Ann Oncol.* 2022;33:S1401–2.
- 33 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: beyond the known frontiers. *World J Gastroenterol.* 2019;25(31):4360–82.
- 34 Li Y, Gao ZH, Qu XJ. The adverse effects of sorafenib in patients with advanced cancers. *Basic Clin Pharmacol Toxicol.* 2015;116(3):216–21.
- 35 Ikeda M, Kobayashi M, Tahara M, Kaneko S. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. *Expert Opin Drug Saf.* 2018;17(11):1095–105.
- 36 Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. *Cancer Treat Rev.* 2019;77:20–8.
- 37 Jin KT, Wang SB, Ying XJ, Lan HR, Lv JQ, Zhang LH, et al. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. *Immunol Lett.* 2020 May;221:61–71.
- 38 Fong KY, Zhao JJ, Sultana R, Lee JX, Lee SY, Chan SL, et al. First-line systemic therapies for advanced hepatocellular carcinoma: a systematic review and patient-level network meta-analysis. *Liver Cancer.* 2023 Feb;12(1):7–18.
- 39 Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. *Lancet Oncol.* 2021 Jul;22(7):977–90.
- 40 Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. *J Hepatol.* 2018 Aug;69(2):353–8.